Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, ... Nature communications 9 (1), 5341, 2018 | 461 | 2018 |
Photoredox mediated nickel catalyzed cross-coupling of thiols with aryl and heteroaryl iodides via thiyl radicals MS Oderinde, M Frenette, DW Robbins, B Aquila, JW Johannes Journal of the American Chemical Society 138 (6), 1760-1763, 2016 | 406 | 2016 |
Current and future roles of artificial intelligence in medicinal chemistry synthesis TJ Struble, JC Alvarez, SP Brown, M Chytil, J Cisar, RL DesJarlais, ... Journal of medicinal chemistry 63 (16), 8667-8682, 2020 | 188 | 2020 |
Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross‐Coupling of Primary Aryl Amines with Aryl Halides MS Oderinde, NH Jones, A Juneau, M Frenette, B Aquila, S Tentarelli, ... Angewandte Chemie 128 (42), 13413-13417, 2016 | 179 | 2016 |
Effects of molecular oxygen, solvent, and light on iridium-photoredox/nickel dual-catalyzed cross-coupling reactions MS Oderinde, A Varela-Alvarez, B Aquila, DW Robbins, JW Johannes The Journal of Organic Chemistry 80 (15), 7642-7651, 2015 | 101 | 2015 |
Structure based design of non-natural peptidic macrocyclic Mcl-1 inhibitors JW Johannes, S Bates, C Beigie, MA Belmonte, J Breen, S Cao, ... ACS medicinal chemistry letters 8 (2), 239-244, 2017 | 74 | 2017 |
Biomimetic Macrocycle-Forming Diels− Alder Reaction of an Iminium Dienophile: Synthetic Studies Directed Toward Gymnodimine JW Johannes, S Wenglowsky, Y Kishi Organic letters 7 (18), 3997-4000, 2005 | 69 | 2005 |
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper … JW Johannes, A Balazs, D Barratt, M Bista, MD Chuba, S Cosulich, ... Journal of Medicinal Chemistry 64 (19), 14498-14512, 2021 | 68 | 2021 |
Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper G Illuzzi, AD Staniszewska, SJ Gill, A Pike, L McWilliams, SE Critchlow, ... Clinical cancer research 28 (21), 4724-4736, 2022 | 63 | 2022 |
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology JW Johannes, L Almeida, B Barlaam, PA Boriack-Sjodin, R Casella, ... ACS medicinal chemistry letters 6 (3), 254-259, 2015 | 60 | 2015 |
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering JW Johannes, L Almeida, K Daly, AD Ferguson, SE Grosskurth, H Guan, ... Bioorganic & medicinal chemistry letters 25 (24), 5743-5747, 2015 | 59 | 2015 |
Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases T Wang, MA Block, S Cowen, AM Davies, E Devereaux, L Gingipalli, ... Bioorganic & medicinal chemistry letters 22 (5), 2063-2069, 2012 | 55 | 2012 |
A Unified and Practical Method for Carbon–Heteroatom Cross‐Coupling Using Nickel/Photo Dual Catalysis RA Escobar, JW Johannes Chemistry–A European Journal 26 (23), 5168-5173, 2020 | 52 | 2020 |
Structure‐based design of selective noncovalent CDK12 inhibitors JW Johannes, CR Denz, N Su, A Wu, AC Impastato, S Mlynarski, ... ChemMedChem 13 (3), 231-235, 2018 | 47 | 2018 |
Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors MM Vasbinder, B Aquila, M Augustin, H Chen, T Cheung, D Cook, L Drew, ... Journal of Medicinal Chemistry 56 (5), 1996-2015, 2013 | 43 | 2013 |
Nickel-catalyzed photoredox-mediated cross-coupling of aryl electrophiles and aryl azides MO Konev, TA McTeague, JW Johannes ACS catalysis 8 (10), 9120-9124, 2018 | 42 | 2018 |
Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer Z Wang, SE Grosskurth, T Cheung, P Petteruti, J Zhang, X Wang, W Wang, ... Cancer research 78 (23), 6691-6702, 2018 | 40 | 2018 |
A Novel method for the direct synthesis of symmetrical and unsymmetrical sulfides and disulfides from aryl halides and ethyl potassium xanthogenate M Soleiman-Beigi, Z Arzehgar Synlett 29 (07), 986-992, 2018 | 32 | 2018 |
Free ligand 1D NMR conformational signatures to enhance structure based drug design of a Mcl-1 inhibitor (AZD5991) and other synthetic macrocycles AYS Balazs, RJ Carbajo, NL Davies, Y Dong, AW Hird, JW Johannes, ... Journal of Medicinal Chemistry 62 (21), 9418-9437, 2019 | 29 | 2019 |
Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers AW Hird, JP Secrist, A Adam, MA Belmonte, E Gangl, F Gibbons, ... Cancer Research 77 (13_Supplement), DDT01-02-DDT01-02, 2017 | 29 | 2017 |